Pfizer Japan Inc
Phase 2/3 of new oral antiviral drug candidates in clinical trials to treat adults living at home with people who test positive for the coronavirus-mediated disease COVID-19 on Monday He said he would start the test. The candidate is called PF007321332 and is co-administered with a low dose of ritonavir to prevent infection. “If successful, we believe that this treatment will help stop the virus early before it is widely replicated. It will prevent symptomatic disease in exposed people and others. It can prevent the onset of infection, “said Michael Dorsten. , MD, PhD. , Pfizer’s Chief Scientific Officer and President of Global R & D and Medical Care. The study enrolls up to 2,660 healthy adults over the age of 18.Pfizer stocks were slightly higher before the market, rising 19% year-to-date, but the Dow Jones Industrial Average averaged 30 stocks.
It has increased by 13.7%.
Pfizer launches Phase 2/3 trial of COVID-19 oral antiviral candidate in adults exposed to the virus
Source link Pfizer launches Phase 2/3 trial of COVID-19 oral antiviral candidate in adults exposed to the virus